Astellas Expands Drug Line In Asia To Offset U.S., Europe Losses
This article was originally published in PharmAsia News
Astellas Pharma is responding to the loss of patent protection on some of its key drugs by turning to Asia as a market where the company can build its drug sales. The patents are being lost in Europe and in the United States, where sales already have weakened. Astellas plans to introduce in China its Vesicare (solifenacin) for overactive bladders and its extended-relief Advagraf (tacrolimus) immunosuppressant in South Korea and Taiwan, all by the end of this year. Next year, Astellas plans to market Advagraf in China and Thailand, pending approval, Mycamine (micafungin) antifungal in India this year and in Indonesia where it already sells its Harmal (tamsulosin) for urinary disorders, sold elsewhere as Flomax. (Click here for more - a subscription may be required
You may also be interested in...
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.